Abstract
Cytotoxic anticancer chemotherapeutic agents generally accompany severe side effects to the hosts, and reduce the host resistance against cancer and infectious diseases, especially by destroying lymphoid cells and bone marrow cells. As a results, many cancer patients die of various kinds of pneumonitis, septicaemia, uremia or other secondary diseases. On the other hand, there is reliable clinical evidence to support the existence of intrinsic resistance against cancer and infectious diseases in the human body. An increase in this resistance may be one of the most important facets in the development of pharmaceutical therapy against such diseases. Based on this concept, we re-examined antitumour effects of many folk remedies which had been long believed to be effective to cancer patients, and then we isolated lentinan having marked antitumour activity from Lentinus edodes, an edible mushroom(Chihara et al. 1970).
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Browder IW, Williams DL, Kitahama A, DiLuzio NR (1984) Modification of post-operative C.albicans sepsis by glucan immunostimulation. Int.J Immunopharmac 6: 19–26
Brown KN (1976) Immunology of parasitic infections. Blackwell Scientific Publication, Oxford, p 268
Byram JE, Sher A, DiPietro J, von Lichtenberg F (1979) Potentiation of schistosome granuloma formation by lentinan-a T-cell adjuvant. Am J Pathol 94: 201–218
Chang KSS (1981) Lentinan-mediated resistance against VSV-encephalitis, Abelson virus-induced tumor, and trophoblastic tumor in mice. In: Aoki et al.(eds) Manipulation of host defence mechanisms. Excerpta Medica, Amsterdam p 88
Chihara G, Hamuro J, Maeda YY, Arai Y, Fukuoka F (1970) Fractionation and purification of the polysaccharides with marked antitumor activity especially lentinan from Lentinus edodes(Berk.) Sing., an edible mushroom. Cancer Res 30: 2776–2781
Chihara G, Maeda YY, Hamuro J, Shiio T, Suga T, Takasuka N, Sasaki T (1987) Antitumour and metastasis-inhibitory activities of lentinan as immunomodulator: An overview. Cancer Detection and Prevention 1987, Supple 1: 423–443
Cook JA, Holbrook TW, Dougherty WJ (1982) Prospective effect of glucan against visceral leishmaniasis in hamsters Infect Immun 37: 1261–1269
DiLuzio NR, Williams DL (1978) Protective effect of glucan against systemic Staphylococcus aureus septicemia in normal and leuchemic mice. Infect Immun 20: 804–810
Hamada C (1981) Inhibition effect of lentinan on tumorigenesis of adenovirus type 12 in mice. In:Aoki T et al.(eds) Manipulation of host defence mechanisms. Excerpta Medica, Amsterdam p 76
Hamuro J, Chihara G (1985) Lentinan, a T-cell oriented immunopotentiator Its experimental and clinical application and possible mechanism of immune modulation. In: Fenichel RL, Chirigos MA(eds) Immune Modulation agents and their mechanisms. Marcel Dekker, New York, p 409
Hamuro J, Röllinghof M, Wagner H (1978) B-1,3-Glucans mediated augmentation of alloreactive murine cytotoxic T-lymphocytes in vivo. Cancer Res 38: 3080–3085
Herlyn D, Kaneko Y, Rorue J, Kaprowski H (1985) Monoclonal antibody-dependent murine macrophage mediated cytotoxicity against human tumor is stimulated by lentinan. Jpn J Cancer Res(Gann) 76: 37–41
Izawa M, Ohno K, Amikura K, Hamuro J (1984) Lentinan augments the production of Interleukin 3 and colony stimulating factor(s). In: Aoki et al.(eds) Manipulation of host defence mechanisms, Excerpta Medica, Amsterdam p 59
Kanai K, Kondo E (1981) Immunomodulating activity of lentinan as demonstrated by frequency limitation on post-chemotherapy relapse in experimental mouse tuberculosis. In: Aoki T et al.(eds) Manipulation of host defence mechanisms, Excepta Medica Amsterdam p 65
Kaneko Y, Yoshida O, Nakagawa R, Yoshida T, Date M, Ogihara S, Shioya S. Matsuzawa Y, Nagashima N, Irie Y, Mimura T, Shinkai H, Yasuda N, Matsuzaki K, Uryu T, Yamamoto N (1990) Inhibition of HIV-1 infectivity with curdlan sulfate in vitro Biochem Pharmacol 39: 793–797
Kawamura T, Numazaki Y (1980) Effect of lentinan on Listeria infection. Proc Jpn Cancer Assoc 39: 134
Maeda YY, Chihara G (1971) Lentinan, a new immunoaccerelator of cell-mediated responces. Nature 229: 634
Maeda YY, Chihara G (1973) The effect of neonatal thymectomy on the antitumour activity of lentinan, carboxymethylpachymaran and zymosan, and their effects on various immune responces. Int J Cancer 11: 153–161
Maeda YY, Watanabe ST, Chihara C, Rokutanda M (1988) Denaturation and renaturation of a P.-1,6;1,3-glucan, lentinan, associated with expression of T-cell-mediated responces. Cancer Res 48: 671–675
Maeda YY, Watanabe ST, Chihara G, Rokutanda M (1984) T-cell mediated vascular dilatation and hemorrhage induced by antitumor polysaccharides Int J Immunopharmac 5: 493–501
Reynolds JA, Kastello MD, Harrington DG, Crabbs CL, Peters CL, Jemski JL, Scott GH, DiLuzio NR (1980) Glucan induced enhansment of host resistance to selected infectious diseases. Infect Immun 30: 51–57
Rose WC, Reed III FC, Siminoff P, Bradner WT (1984) Immunotherapy of Madison 109 lung carcinoma and other murine cancer using lentinan. Cancer Res: 44: 1368–1373
Shiio T, Yugari Y (1981) The antitumor effect of lentinan and the tumor recognition in mice. In: Aoki T et al.(eds) Manipulation of host defence mechanisms. Excerpta Medica, Amsterdam, p 29
Song M, DiLuzio NR (1979) Yeast glucan and immunotherapy of infection diseases. In: Dingle et al.(eds) Lysosomes in Biology and Pathology Vol 6, North Holland, Amsterdam p 553
Suga T, Izawa M, Yamashita A, Chihara G (1990) Infiltration of host cells in rocal tumour sites triggered by the administration of antitumour polysaccharide, lentinan. In Masihi KN, Lange W (eds) Immunotherapeutic prospects of infectious diseases, Springer-Verlag, Heidelberg, in press
Suga T, Maeda YY, Uchida H, Rokutanda M, Chihara G (1986) Macrophage mediated acute-phase transport protein induced by lentinan. Int J Immunopharmac 8: 691–699
Suga T, Shiio T, Maeda YY, Chihara G (1984) Antitumor activity of lentinan in murine syngeneic and autochthonous hosts and its suppressive effect on 3-methyicholanthrene induced carcinogenesis. Cancer Res 44: 5132–5137
Taguchi T, Furue H, Kimura T, Kondo T, Hattori T, Ito I, Ogawa N (1985) End-point result of a randomized controlled study on the treatment of gastrointestinal cancer with a combination of lentinan and chemotherapeutic agents, In: Tsubura T et al.(eds)Rationale of biological modifiers in cancer treatment, Excepta Medica, Amsterdam, p 151
Tochikura TS, Nakashima H, Kaneko Y, Kobayashi N, Yamamoto N (1987) Suppression of human immunodeficiency virus replication by 3’-azido-3’ deoxythymidine in various human hematopoietic cell lines in vitro: Augmentation of the effect by lentinan. Jpn J Cancer Res (Gann) 78: 583–589
White TR, Thompson RCA, Penhale WJ, Chihara G (1988) The effect of lentinan on resistance of mice to Mesocestoides corti. Parasitol Res 74: 563–568
Williams DL, Browder IW, DiLuzio NR (1983) Immunotherapic modification of E. coli induced experimental peritonitis and bacteremia by glucan. Surgery 93: 448–454
Williams DL, DiLuzio NR (1980) Glucan induced modification of murine viral hepatitis, Science 200: 67–69
Yoshida O, Nakashima H, Yoshida T, Kaneko Y, Yamamoto I, Matsuzaki K, Uryu T, Yamamoto N (1989) Sulfation of the immunomodulating polysaccharide lentinan: a novel strategy for antivirals to human immunodeficiency virus ( HIV ), Bioshem Pharmacol 37: 2887–2891
Zákany J, Chihara G, Fachet J (1980) Effect of lentinan on tumour growth in murine allogeneic and syngeneic hosts. Int J Cancer 25: 371–376
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1990 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Chihara, G. (1990). Lentinan and its Related Polysaccharides as Host Defence Potentiators: Their Application to Infectious Diseases and Cancer. In: Masihi, K.N., Lange, W. (eds) Immunotherapeutic Prospects of Infectious Diseases. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-76120-1_2
Download citation
DOI: https://doi.org/10.1007/978-3-642-76120-1_2
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-76122-5
Online ISBN: 978-3-642-76120-1
eBook Packages: Springer Book Archive